The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
and about 80% of patients with the common epithelial cancers it turns out as a result of the research done in recent years do exist that can recognize the products of the mutations but the immune system against them is too small is not vigorous enough
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the fact that 80 of patients have neoantigens on their cancers that are recognized by their immune system
roughly 80% of epithelial tumors had novel neoantigens
more than 80% of those cancers have antigens that are recognized by the host's immune system
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.